DouglasDonaldRossMD

PubMed

• 13 citations
  Loss of terminal deoxynucleotidyl transferase (TDT) activity as a predictor of emergence of resistance to chemotherapy in a case of chronic myelogenous leukemia in bla...
  Douglas D. Ross, Peter H. Wiernik, Prem S. Sarin, Jacqueline Whang-Peng
  Cancer. 1979-11-01
• 189 citations
  Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
  Douglas D. Ross, Judith E. Karp, Tar T. Chen, L. Austin Doyle
  Blood. 2000-07-01
• 36 citations
  Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance
  Douglas D. Ross, L. A. Doyle, Weidong Yang, Yi Tong, B. Cornblatt
  Biochemical Pharmacology. 1995-11-09

Journal Articles

• Concomitant bone marrow involvement by plasma cell myeloma and primary Myelodysplastic syndrome with biclonal complex chromosome anomalies  
  Nanaji, N.M., Chen, Q.C., Singh, Z., Ross, D.D., Elman, A., Zou, Y.S., Leukemia and Lymphoma, 1/1/2015
• Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steriodogenic factor-1  
  Xie, Y., Natarajan, K., Bauer, K.S., Nakanishi, T., Beck, W.T., Moreci, R.S., Jeyasuria, P., Hussain, A., Ross, D.D., Biochim Biophys Acta Gene Regulatory Mechanisms, 1/1/2013
• Drug efflux by Breast Cancer Resistance Protein (BCRP) is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor...  
  Hou, X., Huang, F., Carboni, J.M., Flatten, K., Asmann, Y.W., Ten Eyck, C., Nakanishi, T., Tibodeau, J.D., Ross, D.D., Gottardis, M.M., Erlichman, C., Kaufmann,, S.H.,..., Mol Cancer Ther, 1/1/2011
• Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signaling  
  Nakanishi, T., Chumsri, S., Khakkpour, N., Brodie, A.H., Leyland-Jones, B., Hamburger, A.W., Ross, D.D., Burger, A.M., British Journal of Cancer, 1/1/2010
• Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: A possible target for combination therapy with antiproliferative ami...  
  Fan, X., Ross, D.D., Ganapathy, V., Tamai, I., Nakanishi T, Biochemical Pharmacology, 1/1/2010
• Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2)  
  Tan, K.P, Wang, B., Yang, M.D., Boutros, P., MacAulay, J., Xu, H., Chuang, A., Kosuge, K., Yamamoto, M., Takahashi, S-IO, Wu, A., Ross, D.D., Ito, S, Molecular Pharmacology, 1/1/2010
• Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Cancer Treatment Outcomes  
  Ross, D.D., Nakanishi, T, "Multidrug Resistance in Cancer,” Methods in Mol Biol, University of Pittsburgh Cancer Institute Basic Research Seminar, 1/1/2010
• Preclinical Studies of Vorinostat (Suberoyl­anilide Hydroxamic Acid, SAHA) Combined with Cytosine Arabinoside (ara-C) and Etoposide for Treatment of Acute Leukemias  
  Shiozawa, K., Nakanishi, T., Tan, M., Fang, H-B., Wang, W-C., Edelman, M., Carlton, D., Sausville, E.A., and Ross, D.D., Clinical Cancer Research, 1/1/2009
• SAHA (Zolinza, vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in Balb/c nude mice  
  Shankar, S., Davis, R., Singh, K.P., Kurzrock, R., Ross, D.D., Srivastava, R.K., Mol Cancer Therapeutics, 1/1/2009
• The 44 kDa Pim-1 kinase phosphorylates BCRP/­ABCG2 and promotes its drug resistant activity in human prostate cancer cells  
  Xie, Y., Xu, K., Linn, D., Nakanishi, T., Ross, D.D., Chen, H., Fazli, L., Gleave, M.E., and Qiu, Y, J Biol Chem, 1/8/2008
• Progesterone Receptor Isoforms, PRA and PRB, Differentially Regulate Expression of the Breast Cancer Resistance Protein (BCRP) in Human Placental Choriocarcinoma BeWo ...  
  Wang H, Lee EW, Zhou L, Leung PC, Ross D, Unadkat JD, Mao Q, Mol Pharmacol, 1/1/2008
• Palliative and End-of-Life Care for Medical Residents  
  Ross, D.D. and Wolfsthal, S, MedEdPORTAL, 1/1/2007
• Family Perspectives on Communication With Healthcare Providers During End-of-Life Cancer Care  
  Royak-Schaler, R., Gadalla, S.M., Lemkau, J.P., Ross, D.D., Alexander, S., Scott, D., Oncology Nursing Forum, 1/1/2006
• Readers respond to ‘balancing evidence-based medicine and cultural competence in the quest to end healthcare disparities’  
  Royak-Schaler R, DeYoung C, Khakpour N, Ross D, Tkaczuk K, Gadalla S, MedGenMed, 1/1/2006
• Cyclosporin A, tacrilimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan  
  Gupta, A., Vethanaygam, R.R., Herbert, M.F., Thummel, K.E., Unadkat, J.D., Ross, D.D., and Mao, Q, Cancer Chemotherapy and Pharmacology, 1/1/2006
• Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP ex...  
  Nakanishi, T., Shiozawa, K., Hassel, B.A., and Ross, D.D., BLOOD, 1/1/2006
• Novel 5’ UTR variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-spe...  
  Nakanishi, T., Bailey-Dell, K., Hassel, B., Shiozawa, K., Sullivan, D., Turner, J., Ross, D.D., Cancer Research, 1/1/2006
• Thapsigargin resistance in human prostate cancer cells  
  O’Neill, J., Velalar, C.N., Lee, D.I., Zhang, B., Nakanishi, T., Tang, Y., Selaru, F, Ross, D., Meltzer, S.J., Hussain, A, Cancer, 1/1/2006
• Alterations in the Mitochondrial Proteome of Adriamycin Resistant MCF-7 Breast Cancer Cells  
  Strong, R., Nakanishi, T., Ross, D., Fenselau. C., Journal of Proteome Research, 1/1/2006
• The ErbB3 binding protein Ebp1 suppresses Androgen Receptor mediated gene transcription and tumorigenesis of prostate cancer cells  
  Zhang, Y., Wang, X-W., Jelovac, D., Nakanishi, T., Yu, M-H., Akinmade, D., Goloubeva, O., Ross, D.D., Brodie, A. and Hamburger, A.W., PNAS, Epub, 1/30/2005
• Plasma Pharmacokinetics and Tissue Distribution of the Breast Cancer Resistance Protein (BCRP) Inhibitor Fumitremorgin C (FTC) in SCID Mice Bearing T8 Tumors  
  Garimella TS, Ross DD, Eiseman JL, Mondick J, Joseph E, Nakanishi T, Bates SE, Bauer KS, Cancer Chemotherapy and Pharmacology, 1/1/2005
•  
  Bauer KS, Karp JE, Garimella TS, Wu S, Tan M, and Ross DD, Leukemia Research, 1/1/2005
• Long-term Evaluation of New and Required Coursework in Palliative and End-of-Life Care for Medical Students  
  Ross, DD, Shpritz, D, Hull, MM, Goloubeva, O, J Palliat Med, 1/1/2005
• Interactive effects of HDAC inhibitors and TRAIL in multiple myeloma  
  Fandy T, Shankar S, Singh TR, Ross DD, Sausville E, Srivastava RK, Neoplasia, 1/1/2005
• Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways  
  Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK, International Journal of Molecular Medicine, 1/1/2005
• Join now to see all

Books/Book Chapters

• Resistance of Targeted Anti-Cancer Therapeutics 
  Chapter: Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance 
  Natarajan, K., Baer, M.R., Ross, D.D.Editors: Thomas Efferth.Springer, New York2014
• Acute Myelogenous Leukemia 
  Chapter: Drug Resistance Transporters in AML 
  Page 163 - 173Ross, D.D.Editors: Karp JE.Humana Press, Totowa, NJ2007

Abstracts/Posters

• Phospho-CREB binds directly and specifically to the E1b alternative promoter of mouse Bcrp1/Abcg2 and enhances its transcription
  Xie, Y., Natarajan, K., and Ross, D.D., 8th Annual North American ABC Workshop, Frederick Cancer Research Center, 1/28/2011
• Formative evaluation of Experiential, Competency-Based Palliative and End-Of-Life Care Training For Internal Medical Residents and Medical Oncology Fellows
  Ross, DD, Shpritz, DW, Wolfsthal, SD, Zimrin, AB, Keay, TJ, Fang, H, Schuetz, C, Stapleton, LM, and Weissman, DE, AACE 45th Annual Meeting, J. Cancer Ed, 45th Annual Meeting of the American Association for Cancer Education, 1/9/2011
• Maximal Power Design and Analysis of Drug Combination Studies: Applications to Vorinostat with Cytosine Arabinoside and Etoposide and Other Combination Studies
  Fang, H, Ross DD, Tan, M, AACR 100th Annual Meeting, Washington, DC, 1/1/2010
• Implementation of Experiential, Competency-Based Palliative and End-Of-Life Care Training For Internal Medical Residents and Medical Oncology Fellows
  Ross, DD, Shpritz, DW, Wolfsthal, SD, Zimrin, AB, Keay, TJ, Fang, H, Schuetz, C, Stapleton, LM, and Weissman, DE, AACE 44th Annual Meeting, J. Cancer Ed, 1/1/2010
• Competency Based Experiential Training in Palliative and End-of-Life Care for Internal Medical Residents and Medical Oncology Fellows
  Wolfsthal, S.D., Ross, D.D., Shpritz, D.W., Zimrin, A.B., Keay, T.J., Goloubeva, O.G., Stapleton, L.M., and Weissman, D.E., Alliance for Academic Medicine (AAIM), 1/30/2008
• The 44 kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug resistant activity in human prostate cancer cells
  Yingqiu Xie, Kexin Xu, Douglas Linn, Zhiyong Guo, Takeo Nakanishi, Douglas D. Ross, Yun Qiu, 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 1/12/2008
• Inhibition of HER2 and HER3 phosphorylation can diminish tumor propagating breast cancer cells in vitro and prevent tumor repopulation in NOD/SCID mice
  Saranya Chumsri, Takeo Nakanishi, Pornima Phatak, Brian Leyland-Jones, Douglas D. Ross, Nazanin Khakpour, Anne W. Hamburger, Angelika M. Burger, 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 1/12/2008
• Progress on Implementing a Strategy for Experiential, Competency-Based Palliative and End-of-Life Care Training for Internal Medical Residents and Medical Oncology Fel...
  Ross, D.D., Shpritz, D.W., Wolfsthal, S.D., Zimrin, A.B., Keay, T.J., Goloubeva, O.G., Stapleton, L.M., and Weissman, D.E., American Association for Cancer Education, J. Cancer Ed, 1/1/2008
• Phase I Trial of Vorinostat Combined with Cytarabine and Etoposide in Patients (pts) with Advanced Acute Leukemia and High-Risk Myelodysplastic Syndromes
  Gojo, I, Tan, MT, Shiozawa, K, Nakanishi, T, Burger, AM, Burgess, CL, Egorin, MJ, Baer, MR, Tidwell, ML Srivastava, R, Carrier, F, Scardina, A, Espinoza-Delgado, I, an..., Blood (ASH Annual Meeting Abstracts), 1/1/2008
• Drug efflux through Breast Cancer Resistance Protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor BMS-536924
  Haluska, P., Carboni, J.M., Asmann, Y.W., Ten Eyck, C., Attar, R.M., Tibodeau, J.D., Hou, X., Ross, D.D., Kaufmann, S.H., Gottardis, M.M., Erlichman, C, San Antonio Breast Cancer Symposium, 1/1/2008
• Alternative promoter activity of the human breast cancer resistance protein (BCRP/ABCG2) gene in drug-resistant cells
  Nakanishi T, Natarajan, K, Atchison S, Ross DD, 98th Annual Meetings of AACR, Los Angeles, CA, 1/1/2007
• Identification and characterization of the major alternative promoter controlling Bcrp1 expression in the mouse intestine
  Natarajan K, Nakanishi T, Bauer KA, Ross DD, 98th Annual Meetings of AACR, Los Angeles, CA, 1/1/2007
• Overexpression of HER2/Neu in breast cancer cell lines is associated with an increased side population, presence of ABC transporters, and clonogenicity
  Chumsri S, Nakanishi T, Natarajan K, Phatak P, Hamburger AW, Ross DD, Burger AM, 98th Annual Meetings of AACR, Targ Oncol, Los Angeles, CA, 1/1/2007
• Maximum power experimental design and combination index surface analysis for evaluating interactions of drug combinations, with applications to suberoylanilide hydroxa...
  Fang, H-B, Nakanishi T, Sausville E, Ross DD, Tan M, 98th Annual Meetings of AACR, Los Angeles, CA, 1/1/2007
• Strategy for experiential, competency-based palliative and end-of-life care training for internal medicine residents and medical oncology fellows
  Ross, D.D., Shpritz, D.W., Wolfsthal, S.D., Zimrin, A.B., Keay, T.J., Goloubeva, O.G., Stapleton, L.M., Weissman, D.E., J. Cancer Ed, 1/1/2007
• BCRP expression is functionally upregulated by epidermal growth factor receptor (EGFR, ErbB1)-mediated signaling in human ovarian cancer cell lines, but not in human b...
  Nakanishi T, Shiozawa K, Hamburger AW, Ross DD, 97th Annual Meetings of AACR, Washington, DC, 1/1/2006
• Schedule Dependent Synergy of Suberoylanilide Hydroxamic Acid (SAHA or Vorinostat) in Combination with Cytarabine (ara-C) and Etoposide in HL-60 Human Acute Myeloid Le...
  Shiozawa K, Nakanishi T, Tan M, Fang HB, Edelman MJ, Gojo I, Sausville EA, and Ross DD, 97th Annual Meetings of AACR, Washington, DC, 1/1/2006
• A Novel Statistical Method using Uniform Measures for Evaluating Synergy, Antagonism or Additivity of Drug Combinations, with Applications to Suberoylanilide Hydroxami...
  Fang HB, Shiozawa K, Sausville EA, Ross DD, and Tan M, 97th Annual Meetings of AACR, Washington, DC, 1/1/2006
• Training Program In Palliative And End-Of-Life Care For Internal Medicine Residents At An American Medical School
  Ross DD, Shpritz D, and Wolfstahl SD, European Association for Cancer Education, Birmingham, UK, 1/1/2005
• Mandatory Web Based End-Of-Life Care Training Program For Internal Medicine Residents – Evaluation Of Our Experience With Resident Classes of 2005, 2006, and 2007
  Ross DD, Goloubeva O, Shpritz D, and Wolfstahl SD, 39th Annual Meetings of the American Association for Cancer Education, Cincinnati, OH, 1/1/2005
• Evaluation of required postgraduate palliative care training for internal medicine residents
  Ross DD, Shpritz D, Alexander CS, Carter K, Edelman MJ, Friedley N, Hemani A, Keay TJ, Roy SC, Silverman H, Tasker DJ, Timmel D, Schwartz J, Wolfsthal S, J Cancer Education supplement, 1/1/2004
• Adult tissue-derived side population (SP) cells in the pancreas, liver and bone marrow of the rhesus macaque
  Poliakova L, Pirone A, Farese A, Farney A, Ross D, MacVittie T, 6th International Congress of the Cell Transplant Society, 1/1/2003
• Evaluation of required coursework in palliative and end-of-life care for medical students
  Ross D.D., Shpritz D., Hull M., Goloubeva O, Proceedings of the American Association of Cancer Education, 1/1/2003
• Communication issues in palliative and end-of-life care
  Royak-Schaler R., Ross D.D., Hau­s­man K., Tarzian A., Carter K., Scott D.A., Alex­an­der C.S., Proceedings of the American Association of Cancer Education, 1/1/2003
• Evaluation of a web-based course in end-of-life care for internal medicine residents
  Ross D.D, Shpritz D., Alex­an­der C.S., Carter K., Edel­man M.S., Friedley N., He­mani A., Keay T., Roy S., Silver­man H., Tasker D., Timmel D., Wolf­sthal S, Proceedings of the American Association of Cancer Education, 1/1/2003
• Join now to see all

Lectures

• Breast Cancer Resistance Protein (BCRP; ABCG2): Review, Regulation and Role in Resistance 
  Kanazawa, Japan - 1/24/2014
• Implementation of Competency-based Palliative Care Practices at the UMGCC 
  Baltimore, MD - 1/22/2010
• Managing requests for medically ineffective care 
  Baltimore, MD - 1/8/2010
• Breast Cancer Resistance Protein (BCRP/ABCG2): Impact on Cancer Treatment and Outcomes 
  Detroit, MI - 1/13/2008
• Palliative and end-of-life issues for medical practitioners and the public 
  1/26/2007
• BCRP/ABCG2 and Hematologic Malignancies 
  1/20/2007
• Vorinostat Combined with Cytarabine and Etoposide for Treatment of Refractory Acute Leukemias, MPDs and MDS 
  Atlanta, GA - 1/10/2007
• Clinical and Preclinical Studies of Vorinostat Combined with Cytarabine or Etoposide for Treatment of AML 
  Chicago, IL - 1/4/2007
• Medical doctors and burnout 
  1/3/2007
• Cancer Stem Cells as Novel Therapeutic Targets – Role of BCRP/ABCG2 
  Baltimore, MD - 1/16/2006
• Research Activities in Experimental Therapeutics at the Cancer Center 
  Baltimore, MD - 1/13/2006
• Pain Management Update – 2006 
  Ellicott City, MD - 1/11/2006
• Preclinical Studies of Vorinostat Combined With Cytarabine or Etoposide for Treatment of AML 
  Atlanta, GA - 1/5/2006
• Update of the function of the Breast Cancer Resistance Protein (BCRP/ABCG2) in health and disease 
  Baltimore, MD - 1/4/2006
• What really matters in the end? The impact of law versus other factors (financing, politics) on end-of-life care 
  Baltimore, MD - 1/1/2006
• Role of the ABC Transporter Breast Cancer Resistance Protein (ABCG2) in Health and Disease 
  Baltimore, MD - 1/24/2005
• Translating Discovery into Delivery: the Essential Role of Education 
  Cincinnati, OH - 1/17/2005
• The Challenge of End-of-Life Patient Care 
  Baltimore, MD, 2002, 2003, 2004, 2005 - 1/13/2005
• ABCG2 (BCRP) and Its Role in Drug Absorption, Distribution, Metabolism, and Excretion (ADME) and Drug Resistance 
  Parsippany, NJ - 1/7/2005
• Role of the ABC transporter breast cancer resistance protein (BCRP, ABCG2) in drug disposition 
  Kanazawa, Japan - 1/18/2004
• Function and clinical relevance of BCRP in normal physiology and in cancer drug resistance 
  Tampa, FL; Chicago, IL; Tokyo, Japan - 1/15/2004
• Multidrug resistance and cancer: the role of BCRP 
  Baltimore, MD - 1/9/2004
• Overview and Update on the Role of BCRP/ABCG2 in Multidrug Resistance 
  Bethesda, MD - 1/1/2004
• ATP-Binding Cassette (ABC) transport proteins: From genetic disease to multidrug resistance 
  Detroit, MI - 1/13/2003
• Function and Clinical Relevance of BCRP as a Drug Resistance Protein 
  Amsterdam, the Netherlands; Detroit, MI - 1/12/2003
• Join now to see all

Other

• Thesis title: "Effects of Colony Stimulating Factor (CSF) on Macromolecular Synthesis in Mouse Bone Marrow Cultures" 
  Emory University
  Atlanta, GA - 1/1/1972